Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non–Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Treatment of locally advanced non–small cell lung cancer (NSCLC) remains challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with concurrent chemoradiation (CCRT) was based on results of preclinical research and prospective clinical studies; however, no randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Nan, Liang, Jun, Zhou, Zongmei, Chen, Dongfu, Fu, Zhixue, Yang, Xu, Feng, QinFu, Hui, Zhouguang, Xiao, Zefen, Lv, Jima, Wang, Xiaozhen, Zhang, Tao, Wang, Xin, Deng, Lei, Wang, Wenqing, Wang, Jingbo, Liu, Lipin, Hu, Chen, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991217/
https://www.ncbi.nlm.nih.gov/pubmed/31851351
http://dx.doi.org/10.1001/jamanetworkopen.2019.18070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991217/
https://www.ncbi.nlm.nih.gov/pubmed/31851351
http://dx.doi.org/10.1001/jamanetworkopen.2019.18070

Ejemplares similares